Efficacy

Trodelvy (sacituzumab govitecan-hziy) Efficacy in Breast Cancer

Trodelvy, also known as sacituzumab govitecan-hziy, is a novel antibody-drug conjugate specifically approved for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. The efficacy of Trodelvy was demonstrated in a study known as IMMU-132-01, which showed a significant improvement in overall response rate (ORR) and median progression-free survival (PFS) in patients with TNBC. The ORR was particularly notable in a heavily pretreated population, indicating a potential new standard of care for this aggressive form of breast cancer.

Further clinical trials have continued to support the efficacy of Trodelvy in metastatic TNBC. The ASCENT study, a phase 3 trial, confirmed the benefits observed in earlier studies, showing a statistically significant improvement in overall survival (OS) for patients treated with Trodelvy compared to those receiving standard chemotherapy. These results solidified Trodelvy's role as an important therapeutic option for patients with metastatic TNBC who have limited treatment options.

Phesgo (pertuzumab, trastuzumab, and hyaluronidase) Efficacy in Breast Cancer

Phesgo is a combination of two monoclonal antibodies, pertuzumab and trastuzumab, with the enzyme hyaluronidase, designed for subcutaneous injection. This combination is indicated for the treatment of patients with HER2-positive breast cancer. The efficacy of Phesgo has been established based on studies that originally proved the efficacy of intravenous pertuzumab and trastuzumab. The pivotal study that led to the approval of Phesgo was the FeDeriCa trial, which demonstrated non-inferior levels of pertuzumab and trastuzumab in the blood of patients receiving Phesgo compared to those receiving the intravenous formulations of the two antibodies.

Phesgo has shown efficacy in both the neoadjuvant (pre-surgery) and adjuvant (post-surgery) settings for HER2-positive breast cancer. In the neoadjuvant setting, the combination of Phesgo with chemotherapy has led to high rates of pathological complete response, which is associated with a better prognosis. In the adjuvant setting, Phesgo continues to demonstrate a reduction in the risk of breast cancer recurrence and death, making it a valuable treatment option for patients with HER2-positive breast cancer. The convenience of subcutaneous administration and the reduced administration time are additional benefits that may improve the quality of life for patients undergoing treatment.